Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should KnowZacks Investment Research • 11/08/24
Immunocore reports third quarter financial results and provides a business updateGlobeNewsWire • 11/06/24
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerGlobeNewsWire • 09/14/24
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma AppealSeeking Alpha • 08/12/24
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseGlobeNewsWire • 06/01/24
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024GlobeNewsWire • 05/31/24
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaGlobeNewsWire • 05/29/24
Immunocore reports first quarter financial results and provides a business updateGlobeNewsWire • 05/08/24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateGlobeNewsWire • 02/28/24
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialGlobeNewsWire • 02/22/24
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024GlobeNewsWire • 02/21/24
